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ABSTRACT
Runx1 is a developmentally regulated transcription
factor that is essential for haemopoiesis. Runx1 can
bind as a monomer to the core consensus sequence
TGTGG, but binds more efficiently as a hetero-dimer
together with the non-DNA binding protein CBFb as
a complex termed core binding factor (CBF). Here,
we demonstrated that CBF can also assemble as a
dimeric complex on two overlapping Runx1 sites
within the palindromic sequence TGTGGCTGCCCA
CA in the human granulocyte macrophage colony-
stimulating factor enhancer. Furthermore, we
demonstrated that binding of Runx1 to the
enhancer is rigidly controlled at the level of chroma-
tin accessibility, and is dependent upon prior induc-
tion of NFAT and AP-1, which disrupt a positioned
nucleosome in this region. We employed in vivo
footprinting to demonstrate that, upon activation
of the enhancer, both sites are efficiently
occupied. In vitro binding assays confirmed that
two CBF complexes can bind this site simultaneous-
ly, and transfection assays demonstrated that both
sites contribute significantly to enhancer function.
Computer modelling based on the Runx1/CBFb/
DNA crystal structure further revealed that two
molecules of CBF could potentially bind to this
class of palindromic sequence as a dimeric
complex in a conformation whereby both Runx1
and CBFb within the two CBF complexes are
closely aligned.
INTRODUCTION
Runx1 (also known as AML1, CBFa2 or PEBP2aB) is a
Runt-domain transcription factor (1,2) that is essential for
haemopoiesis (3,4). Runx1 is a member of a conserved
family of closely related proteins that include mammalian
Runx1, Runx2 and Runx3, and the Drosophila protein
Runt (1,2). Runx1 binds to TGTGGNNN core sequences,
typically TGTGGTTT or TGTGGTCA, as a heterodimer
of Runx1 and CBFb, termed core binding factor (CBF)
(2,5,6). Although CBFb does not directly contact DNA, it
helps to stabilize Runx1 binding (2). While TGTGGT is
the most commonly observed natural CBF-binding
sequence, in vitro studies reveal that TGCGGT is also a
high aﬃnity, but much less often encountered, CBF-
binding sequence (2,5,7).
Runx1 binds to DNA via the Runt domain, which
shares some similarity with the Rel domain of NF-kB/
Rel family proteins that also recognize GG core sequences
(8,9). However, NF-kB binds as an obligate dimer that
employs two Rel family proteins to bind to palindromic
sequences such as GGGAAATTCCC (10). This is in
contrast to Runx1 which interacts eﬃciently with single
TGTGGNNN consensus motifs (6). The crystal structure
of a Runx1-Runt domain/CBFb complex bound to the
DNA sequence TGCGGTTG has been determined, re-
vealing contacts with both the bases and the phosphate
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results were obtained by a parallel study of the Runx1
binding site TGTGGTTG (12). Runx1 clamps the phos-
phate backbone between the major and minor groove,
while forming Rel-like base-speciﬁc contacts with the
GG sequence in the major groove (11). In this way,
Runx1 utilizes multiple protein:DNA contacts to enable
eﬃcient binding to single sites (11).
Runx1 synergizes with a variety of other factors to
regulate composite elements. For example, Runx1 and
Ets-1 interact directly and bind cooperatively to enhancers
within the TCRa and TCRb loci (13,14). Runx1 and
C/EBP family proteins synergize in the activation of
adjacent binding sites within the M-CSF receptor gene
promoter (15). Runx1 and c-Myb synergize in the activa-
tion of adjacent sites in the TCR-d enhancer, although in
this instance synergy does not depend on cooperative
binding (16). Runx1 also possesses an interaction
domain within the C terminal region that mediates
homodimerization, and this may promote binding to regu-
latory elements containing multiple Runx1 binding sites
(17). The homodimerization domain appears to be
distinct from the region of Runx1 required for interaction
with other factors, such as Ets-1 (14). This domain is less
structured than the Runt domain, and no detailed deter-
mination of its structure is available.
Runx1 shares some similarities with another class of Rel
domain transcription factor, the NFAT family of proteins,
which bind to GGAAANN consensus sequences. Like
Runx1, NFAT uses multiple interactions to bind to
DNA eﬃciently as a monomer. NFAT uses a single Rel
domain to bind in the major groove to an essential GGA
core sequence, and also has contacts in the minor groove
along the next 4-bp downstream of the GGA core (18).
NFAT typically functions and binds cooperatively
together with other transcription factors such as AP-1
(18,19). However, NFAT family proteins can also bind
as homodimers to NF-kB-like sequences conforming to
the consensus sequence GGAAATTCC (18,20,21). This
raises the possibility that Runx1, like NFAT, might also
be able to bind to palindromic sequences containing two
overlapping Runx1 binding sites. However, to date we are
not aware of any reports of such examples.
The human granulocyte macrophage colony-
stimulating factor (GM-CSF or CSF2) gene is a key
target of regulation by Runx1 (22–24). GM-CSF is a
pro-inﬂammatory cytokine produced by activated T cells
and mast cells that is induced by stimuli that activate the
immune system. The expression of the human GM-CSF
gene is under the control of a promoter region located just
upstream of the transcription start site and an inducible
enhancer located 3-kb upstream, which are both activated
by kinase and calcium signalling pathways that in T cells
are activated via the T-cell receptor (TCR) (19,25–27). We
and others have previously demonstrated the presence of
functional Runx1 sites in both the GM-CSF promoter
(22–24) and the inducible enhancer (22). GM-CSF gene
expression can also be inhibited by the repressive
AML1/ETO fusion protein found in t(8;21) chromosomal
translocations in acute myeloid leukaemia (23,24). These
translocations delete the homo-dimerization domain, and
the addition of the ETO domain converts Runx1 from an
activator to a repressor.
The GM-CSF enhancer is deﬁned as a 717-bp BglII
fragment of DNA that requires interactions with
multiple transcription factor sites for function (25,28).
Within the GM-CSF enhancer, Runx1 binds to the
GM450 element within a region that is normally
occluded by a positioned nucleosome (Figure 1A; 28,29).
Activation of the enhancer by TCR signalling pathways
results in recruitment of NFAT and AP-1 to sites located
within this same nucleosome (N2) and to additional sites
in an adjacent nucleosome (N1), leading to the rapid
eviction of both nucleosomes (summarized in
Figure 1A). This process results in the rapid creation of
a DNase I hypersensitive site (DHS), a substantial
increase in chromatin accessibility, and the recruitment
of Runx1 to a site that was previously unoccupied. This
mechanism thereby allows constitutively expressed factors
such as Runx1 and Sp1 to bind in a highly inducible
fashion.
In this study, we demonstrated that the GM-CSF
enhancer GM450 Runx1 binding site TGTGGCTGCCC
ACA actually has two overlapping TGTGGNNN
Runx1-like elements where the TGTGG core sequences
(underlined) exist 4bp apart within this palindromic
sequence. Furthermore, we obtained evidence that both
sites become occupied in activated T cells and mast cells,
and demonstrated that both sites contribute to enhancer
function. Computer modelling predicted that the palin-
dromic element is able to accommodate binding of two
Runx1/CBFb complexes closely aligned on the same face
of the DNA helix to form multiple close associations
along an axis perpendicular to the DNA.
MATERIALS AND METHODS
Cell culture
The CEM and Jurkat human T-cell lines were cultured in
RPMI (Invitrogen) supplemented with 10% FCS, 4g/l
D-glucose, 1mM sodium pyruvate, 1 MEM essential
amino acids (Invitrogen), 1 MEM non-essential amino
acids (Invitrogen), 100U/ml penicillin and 100mg/ml
streptomycin. C42 human IL-3/GM-CSF transgenic
mouse T lymphoblasts and mast cells were prepared and
cultured as described previously (29,30).
In vivo footprinting analyses
Footprinting analyses were performed essentially as
described (31,32). C42 transgenic mouse T lymphoblasts
were either stimulated for 4h with 20ng/ml phorbol
12-myristate 13-acetate (PMA) and 1mM calcium iono-
phore A23187, or left unstimulated, before treatment
with 0.2% dimethyl sulphate (DMS) in phosphate
buﬀered saline (PBS) for 5min at room temperature.
Speciﬁc DNA cleavage sites were detected using
ligation-mediated (LM)-PCR as described (31,32). These
analyses were performed with two sets of 3 nested primers
designed to detect DNA cleavage sites on either the upper
or the lower strand of the GM420/GM450 region of
the human GM-CSF enhancer, plus the linker primer.
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the biotinylated primer used at the ﬁrst stage, EP for the
primer used at the second PCR stage and EL for those
used in the ﬁnal labelling stage. The 50 primers used to
detect cleavage on the lower strand (plus their annealing
temperatures shown in brackets) were EB3F2, CACAGC
CCCATCGGAGC (52 C); EP3F20, CTGAGTCAGCAT
GGCTGGC (62 C); EL3F, GCATGGCTGGCTATCGG
TTGACACTG (68 C). The 30 primers used to detect
cleavage on the upper strand (plus their annealing tem-
peratures) were EB2R2, GCCCAAGTCAGCACAAAC
(56 C); EP2R, GTCAGCACAAACAGGACAGAAATC
(64 C); EL2R20, AGGACAGAAATCCATGGGTTTG
GTGATG (64 C).
Electrophoretic mobility shift assays
To study binding of puriﬁed CBF, we obtained a sample
of the puriﬁed recombinant Runx1/CBFb complexes that
had been used previously by Bravo et al. (11) to prepare
crystals of CBF bound to DNA. These complexes con-
tained just the His-tagged Runt domain region of Runx1
(residues 50–183), and residues 2–135 of CBFb. To study
binding of native CBF complexes we prepared nuclear
extracts from unstimulated Jurkat T cells, essentially as
described previously (25).
Double stranded oligonucleotides were labelled by
end-ﬁlling with [a-
32P]-dCTP plus unlabelled dATP,
dGTP and dTTP, and the labelled probes were puriﬁed
by polyacrylamide gel electrophoresis. 6mg of nuclear
extract protein was incubated with 0.2ng of labelled
probe, and 3mg of poly(dI.dC) in a 16ml reaction, contain-
ing 10% glycerol, 20mM HEPES, 30mM KCl, 30mM
NaCl, 3mM MgCl2, 1% DTT, 0.1mM PMSF, 5mg/ml
aprotinin, 5mg/ml leupeptin, for 10min at room tempera-
ture ( 22 C) and 10min on ice before analysis on 4%
polyacrylamide gels run at 4 C. For super-shift assays
0.5ml of Runx1 antibody (Santa Cruz C19 or Santa
Cruz N20), or control IgG (Millipore 12-370) was
incubated with the nuclear extract for 10min at room
temperature before addition to the above reaction.
Competition assays were carried out by addition of com-
petitor at stated concentrations in a 1ml volume to nuclear
extract and incubated for 10min on ice before addition of
0.2ng of labelled probe and further incubation for 10min
on ice. Electrophoretic mobility shift assays (EMSAs) of
recombinant puriﬁed CBF were performed by incubating
Figure 1. Transcription factors and nucleosomes associated with the human GM-CSF enhancer. (A) Map of the 717bp BglII fragment of the
enhancer showing the previously determined locations of positioned nucleosomes (N0–N3) and transcription factors bound to the GM-CSF enhancer
in T cells before and after stimulation with PMA and calcium ionophore. The composite NFAT/AP-1 elements are termed GM330 and GM420, and
the Runx1 element is termed GM450. The dotted ovals signify nucleosomes that become mobilized after stimulation which do not reside in ﬁxed
positions. (B) In vivo DMS footprints within the GM-CSF enhancer. Cultured C42 transgenic mouse T cells and mast cells were assayed before ( )
and after (+) stimulation for 4h with PMA and calcium ionophore. Either genomic DNA (G) or intact cells were treated with DMS, and the
modiﬁed bases were cleaved with piperidine and identiﬁed by polyacrylamide gel electrophoresis of LM-PCR products. Open circles indicate
protected bases, and ﬁlled circles indicate hyper-reactive bases. Bases are numbered relative to the upstream BglII site. (C) Quantiﬁcation of the
in vivo protection of the CBF site on the lower DNA strand. These densitometric traces of lanes 9 (nil) and 10 (PMA/I) in Figure 1B reveal DMS
reactivity in mast cells before and after stimulation.
6126 Nucleic Acids Research, 2010,Vol.38, No. 180.25–2.0 pmol of CBF with 0.2ng of labelled probe and
100ng of poly(dI.dC) in a 16ml reaction containing 10%
glycerol, 20mM HEPES pH7.9, 50mM NaCl, 80mM
KCl, 3mM MgCl2, 1% DTT, 0.1mM PMSF, 5mg/ml
aprotinin, 5mg/ml leupeptin, 0.1mg/ml BSA at room tem-
perature for 10min and 10min on ice before analysis on
4% polyacrylamide gels run at 4 C.
The oligonucleotides used to prepare DNA probes had
the following sequences, which include a 2 base 50
overhang at each end:
TCR-d Runx1, AGGCATGTGGTTTCCAACCGTT
and TGAACGGTTGGAAACCACATGC;
Ideal, AGATGTGTGGTTAACCACAAAC
and AGGTTTGTGGTTAACCACACAT;
Ideal1 AGATGTGTGGTTAAGGACAAAC
and AGGTTTGTCCTTAACCACACAT.
Crystal, AGATGTGCGGTCGACCGCAAAC
and AGGTTTGCGGTCGACCGCACAT;
WT GM450, AGATGTGTGGCTGCCCACAAAC
and AGGTTTGTGGGCAGCCACACAT;
GM450443, AGATCTCTCACTGCCCACAAAC
and AGGTTTGTGGGCAGTGAGAGAT;
GM450452, AGATGTGTGGCTGCGTAGAAAC
and AGGTTTCTACGCAGCCACACAT;
GM450443/452, AGATCTCTCACTGCGTAGAAAC
and AGGTTTCTACGCAGTGAGAGAT.
Autoradiography and densitometry
Images were collected on a BioRad Pharos FX Plus
phosphorimager. Densitometry and band quantitation
was performed using BioRad Quantity One software.
Plasmid construction
The previously described constructs pGM and pGM-
GME contain the  627 to +28 region of the human
GM-CSF promoter (GM627) in the absence or presence
of a 717bp Bgl II fragment of the human GM-CSF
enhancer, respectively (33), inserted into the ﬁreﬂy
luciferase reporter gene plasmid pXPG which includes
highly eﬃcient transcription termination and
polyadenylation elements upstream of the enhancer (34).
Site-directed mutagenesis was performed as previously
described (28) to change the TGTGG core sequences
located at positions 443 and 452 in the GM-CSF
enhancer to TGTCC, as indicated in Figure 3. After mu-
tagenesis was completed, the full sequence of the enhancer
in isolated clones was determined, and if correct, was
recloned into pGM so as to avoid any potential additional
unanticipated mutations elsewhere in the plasmids.
The Renilla luciferase control vector pXRL-GME was
created by excising just the ﬁreﬂy luciferase gene from the
pXPG-based vector pGM-GME (33) by digestion with
Xba I plus a partial digestion by HindIII, followed by
insertion of a HindIII–Xba I of the Renilla luciferase
gene excised from the control plasmid pRL-TK
(Promega). This vector retains the same conﬁguration of
vector backbone, upstream SV40 polyA/termination sites,
and GM-CSF enhancer and promoter as in pGM-GME,
and is designed to respond in the same way upon trans-
fection and stimulation.
Transient transfection and luciferase assays
Aliquots of 4.5 10
6 Jurkat T cells were transfected by
electroporation with plasmid DNA puriﬁed by two
rounds of CsCl gradient centrifugation. Cells were trans-
fected with 5mg of Fireﬂy luciferase plasmid plus 1mgo f
the control pXRL-GME Renilla luciferase plasmid. Cells
were cultured for  21h post-transfection, before stimula-
tion with 20ng/ml PMA and 2mM calcium ionophore
A23187 for 8h. Cells were then washed in PBS and
assayed for luciferase reporter gene activities using the
Promega dual luciferase assay kit and a Berthold
Mithras LB-940 microplate luminometer. Data were col-
lected from at least two independently prepared clones of
each construct, which were in each case found to behave in
like fashion. A minimum of 6, and up to 21 independent
transfections were performed for each construct.
Computational modelling of the dimeric form of Runx1-
CBFb-DNA ternary complex
An extended and detailed explanation of the computation-
al modelling and reﬁnement of complex can be found in
the Supplementary Methods. Brieﬂy, the Runt1-CBFb-
DNA coordinates deﬁned in Bravo et al. (11, 35) were
superimposed over a model of guide B-DNA containing
two Runx1 DNA binding sites generated using the nucleic
acid builder tool (36) in the AmberTool package and the
21bp GM-CSF enhancer sequence ATGTGTGGC
TGCCCACAAAAC. The crystal structure of the human
Runx1-CBFb-DNA ternary complex (11) was used as
template to model two Runx1–CBFb complexes bound
to the guide B-DNA using MODELLER (37).
Sequences and templates were aligned so that DNA mol-
ecules of the template were aligned to the corresponding
DNA binding sites in the guide B-DNA preserving the
native Runt1–CBFb–DNA interactions described in the
crystal structure (11). The reﬁnement of the model con-
sisted of two rounds of energy minimization and a short
molecular dynamic simulation of the solvated complex in
order to ensure a reasonable stereochemical geometry,
resolve steric hindrances, and assess the stability of the
complex. The energy minimization and molecular
dynamic simulation was performed in AMBER 10 (38)
using the ﬀ99SB force ﬁeld (39), as follows: On the ﬁrst
round of minimization, protein and DNA atoms were
kept restrained and solvent was relaxed. On the second
round, restraints on DNA and protein atoms, with the
exception of those mediating the interactions between
protein and DNA, were lifted and system was further
minimized. The temperature of the system was then
raised gradually to reach 300K, while remaining restraints
were also gradually removed during the heating process.
Finally, the system was equilibrated for 0.5ns and
simulated for 4ns. The ﬁnal model was obtained after
clustering of the entire molecular dynamic simulation,
selecting a representative on each cluster, and assessing
the quality of each representative using PROCHECK
(40). The convergence of the simulation and stability of
the complex was ensured by plotting the root mean square
deviation and total energy as a function of the simulation
time.
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Runx1 binds to 2 overlapping sites within the GM-CSF
enhancer in vivo upon stimulation
We previously deﬁned the GM450 Runx1 binding site TG
CCCACA that has a TGTGG core sequence located at
position 452 within the human GM-CSF enhancer (22).
This site forms speciﬁc Runx1/CBFb complexes as previ-
ously deﬁned with the aid of speciﬁc antibodies and DNA
competitors, and it can be used to functionally replace the
Runx1 site located within the GM–CSF promoter (22). To
study the regulation of the human GM-CSF locus in
deﬁned populations of normal cells, we employed the
transgenic mouse line C42 containing the intact human
GM-CSF locus on a 130kb BAC segment of DNA (30).
To study Runx1 interactions with the GM-CSF enhancer
inside live cells we employed DMS in vivo footprinting of
T cells and mast cells prepared from C42 mice (29)
(Figure 1B). With this assay we can identify sites of
in vivo protein:DNA interactions by treating cells with
dimethyl sulphate (DMS), which modiﬁes any G bases
that are not occupied by interacting factors. To this end,
cells were treated with DMS before ( ) or after (+) stimu-
lation for 4 hours with 20ng/ml PMA and 2mM calcium
ionophore A23187. As a control for protein-free DNA, we
also treated puriﬁed genomic DNA with DMS (G).
Modiﬁed bases were cleaved by incubation with piperi-
dine, and the speciﬁc cleavage sites were detected by
ligation-mediated PCR. Figure 1B displays the results
obtained after analysis of sites on both the upper and
the lower strands of DNA. The results are summarized
below with protected bases marked by open circles, and
hypersensitive bases marked with ﬁlled circles. Before
stimulation, there was no evidence for any interactions
between any factors and the enhancer, as the patterns
were essentially the same as those obtained by treating
genomic DNA with DMS. After stimulation, there was
clear evidence of eﬃcient binding of factors to the
Runx1, NFAT and AP-1 sites within this region of the
enhancer. Furthermore, the Runx1 site supported not
just one, but two distinct sets of footprints. In addition
to binding at the previously deﬁned TGTGG motif at
position 452 (lower strand, lanes 8 and 10), there was
strong protection of the Runx1-like element TGTGGCT
G located at position 443 (upper strand, lanes 3 and 5).
There was also a hypersensitive reaction with a G at
position 451 on the lower strand, which is symptomatic
of an altered DNA conformation induced by factor
binding.
Particularly in the mast cells, it was evident that there
was very strong protection of both Runx1 sites (lanes 5
and 10), indicating that both sites are likely to be stably
occupied simultaneously in a substantial proportion of
cells. Quantitation of a densitometric analysis of the
data in lane 10 (for the lower strand) in stimulated mast
cells (Figure 1C) indicated that only about 16% of all G
bases at position 455 within the motif at position 452
remained accessible. A similar densitometric analysis of
lane 5 (the upper strand) indicated that only 34% of G
bases at positions 444 and 446 within the motif at position
443 remained accessible after stimulation (data not
shown). Based on this, we can calculate that 66% of all
motifs at position 443 on the upper strand become
occupied. If only 16% of motifs at position 452 on the
lower strand remain free, then this implies that a minimum
of 50% (and maximum of 66%) of all GM450 palindrom-
ic Runx1 sites must be stably occupied at both sites in
stimulated mast cells.
The GM-CSF enhancer Runx1 element can recruit two
CBF complexes at the same time
We used EMSAs to study the in vitro binding of recom-
binant CBF complexes to the Runx1 sites (Figure 2A and
B). For this purpose, we obtained a sample of the original
puriﬁed recombinant CBF complex that had been used
previously by Bravo et al to determine the crystal structure
of the CBF/DNA complex (11). This recombinant CBF
contained the His-tagged Runt domain region of Runx1
(residues 50–183), and the region of CBFb (residues
2–135) that mediates interactions with Runx1. With 0.25
pmol of CBF (lane 1), two diﬀerent mobility complexes
were observed with the wild type probe (WT GM450).
Although we have been unable to determine why two dif-
ferent mobility complexes are detected, it is likely that that
they both contain a single molecule of Runx1, because
both complexes were still detected when either the
position 443 or 452 Runx1 sites were mutated individually
(lanes 5 and 8). These complexes were both regarded as
being speciﬁc for the TGTGG motifs, because no binding
was detected when both Runx1 sites were mutated simul-
taneously (lanes 11–13). It is possible that the lower band
represents a Runx1–DNA complex, from which CBFb has
dissociated, but we have been unable to conﬁrm this.
When amounts of up to 2 pmol of recombinant CBF
were added to the intact GM450 Runx1 probe, increasing
amounts of a third lower mobility complex were observed
(lanes 2–4). This upper complex was assumed to be a
dimeric CBF complex containing two Runx1/CBFb
heterodimers, because it was not detected when either in-
dividual Runx1 site was mutated (lanes 5–10, Figure 2B).
In one published study, the structure of the CBF/DNA
complex was determined using the DNA sequence TGCG
GTTG. To determine whether we could use this structure
as a basis for constructing a computer model of a dimeric
complex, we designed the palindrome TGCGGTCGACC
GCA that contains two overlapping TGCGGTCG motifs
on opposite strands in the same arrangement as the two
Runx1 sites in the GM-CSF enhancer (designated as
Crystal in Figure 2A). In EMSAs, the crystal palindrome
sequence was also capable of assembling a dimeric CBF
complex, slightly more eﬃciently than the GM450
sequence (compare the 0.25 pmol EMSAs in lanes 1 and
14 in Figure 2B).
We next studied the binding of intact natural CBF
complexes to the GM450 and crystal palindromic Runx1
sites using Jurkat human T cell nuclear extracts in EMSAs
(Figure 2C). However, because neither of these palin-
dromes conforms to the preferred TGTGGTCA or TGT
GGTTT consensus, we also designed an additional palin-
dromic probe containing the sequence TGTGGTTAACC
ACA that matches the ideal consensus TGTGGTTA on
6128 Nucleic Acids Research, 2010,Vol.38, No. 18Figure 2. EMSAs of the GM450 Runx1 binding site. (A) Sequences of the wild-type and mutated GM450 Runx1-binding probes, plus the Ideal, the
Ideal1 and the crystal structure-based palindrome sequence used in (B–G), and the TCRd single Runx1 site. The Crystal sequence is a palindrome
derived from the DNA sequence used to prepare crystals by Bravo et al. (11). The ideal sequence is a palindrome derived from the ideal Runx1
consensus binding site, and the Ideal1 sequence has the second Runx1 site in this element mutated. The 8-bp regions spanned by the two Runx1
binding sites are indicated by bars above the sequence, and the mutated GG core elements are shown as underlined in bold. Bases in lower case
represent 2 base 50 overhangs at each end that become double stranded when probes are labelled. (B) EMSAs with increasing concentrations
recombinant Runx1/CBFb complexes binding to the wild-type and mutated GM450 sequences and the Crystal sequence. Bands corresponding to
a monomer and a dimer of Runx1 are marked. (C and D) EMSAs with 6mg Jurkat cell nuclear extract with (C) the wild-type GM450 (lane 1), the
mutated GM450443 (lane 2) and the crystal (lane 3) sequences and (D) the ideal sequence (lane 1) in the presence or absence of an antibody against
either the N-terminal (Runx–N) (lane 2) or C-terminal (Runx-C) (lane 3) of Runx1, or control IgG (lane 4). (E) Competition assay with 6mgo f
Jurkat nuclear extract bound to labelled Ideal probe (lane 1) and competed with 25ng of either Ideal (lane 2), TCRd (lane 3) or GM450443/452
(lane 4) unlabelled oligonucleotides. (F) EMSAs with 6mg of Jurkat cell nuclear extract bound to the Ideal probe (lanes 1 and 7) and competed with
increasing amounts of either unlabelled ideal (lanes 2–6) or Ideal1 (lanes 8–12) oligonucleotides. (G) Densitometric quantiﬁcation of the EMSAs in
(F) showing the proportion of the monomeric and dimeric complexes remaining in the presence of competing Ideal or mutated Ideal1
oligonucleotides.
Nucleic Acids Research, 2010,Vol.38, No. 18 6129both strands (designated as Ideal in Figures 2A). Both the
GM450 and Crystal probes supported the binding of what
appeared to be monomeric and dimeric CBF complexes
(Figure 2C). This conclusion was supported by the fact
that a mutation of the 443 site led to disappearance of
the lower mobility complex.
The Ideal palindromic Runx1 consensus probe also
formed two distinct complexes that were assumed to be
CBF monomer and dimer complexes (lane 1 in Figure 2D
and E). The designated CBF monomer and dimer
complexes were both conﬁrmed as speciﬁc Runx1
complexes because they (i) were both super-shifted by
two diﬀerent Runx1 antibodies (lanes 2 and 3,
Figure 2D), but not by control IgG (lane 4, Figure 2D),
and (ii) were both inhibited by oligonucleotides containing
either the Ideal Runx1 palindrome or a single Runx1 site
from the TCRd locus (lanes 2 and 3, Figure 2E), but not
by GM450 oligonucleotides in which both Runx1 sites had
been mutated (443/452, lane 4, Figure 2E). Taken
together, the in vitro and in vivo binding studies both
support the conclusion that intact Runx1/CBFb
complexes can eﬃciently assemble as a dimeric complex
on palindromic Runx1 binding sites. Note that in this
structure the Runx1 Rel-like domains contact palindromic
GG elements in a conformation, and at a spacing (i.e.
GGNNNNCC) similar to that that observed for the Rel
domains within NFAT dimers and NF-kB complexes,
which typically bind to GGNNNNNCC elements.
Although the assembly of CBF dimers on DNA is not
as cooperative as either NFAT or NF-kB proteins (20), we
attempted to address the issue of cooperativity by testing
diﬀerent probes as competitors (Figure 2E and F). To this
end, we studied the binding of native CBF complexes to
the Ideal palindromic probe in the presence of oligo-
nucleotides containing either the Ideal palindromic
sequence (lanes 2–6, Figure 2F) or the Ideal sequence
with the second Runx1 site mutated (Ideal1, lanes 8–12,
Figure 2F). The percentage of the monomer and dimer
complexes remaining in the presence of increasing
amounts of competitor was calculated by densitometry
and plotted in Figure 2G. This analysis revealed that the
binding properties of two Runx1 sites in one sequence are
not just additive, but that a dimeric element is a substan-
tially stronger competitor than a similar element contain-
ing a single binding site. This raises the possibility that
CBF dimer formation may be assisted by interactions
between Runx1 and/or CBFb.
Both TGTGG motifs contribute to GM-CSF enhancer
function
To study the functions of the two TGTGG motifs at pos-
itions 443 and 452 in the GM-CSF enhancer, we per-
formed transient transfection assays in the CEM and
Jurkat T cell lines. These assays used the previously
deﬁned luciferase plasmid pGM-GME (26) containing a
717bp Bgl II fragment of the human GM-CSF enhancer
inserted upstream of a  627 to +28 segment of the
GM-CSF promoter in the luciferase vector pXPG (41).
This plasmid was assayed in parallel with derivatives of
pGM-GME containing mutations in either one or both of
the position 443 and 452 TGTGG motifs, plus the plasmid
pGM containing just the GM-CSF promoter (26). To
control for both transfection and stimulation eﬃciency
at the same time, we co-transfected cells with the
plasmid pXRL-GME. This plasmid was created from
pGM-GME by excising the ﬁreﬂy luciferase gene and
replacing it with the Renilla luciferase gene.
Fireﬂy and Renilla luciferase plasmids were
co-transfected into cells that were then cultured for
 21h, before stimulating the cells for 8 hours with
20ng/ml PMA and 2mM calcium ionophore A23187,
and harvesting of extracts for dual luciferase assays. We
ﬁrst conﬁrmed that there was no unwanted cross-
contamination of activities between ﬁreﬂy and Renilla
luciferase assays by transfecting Jurkat cells with each
plasmid alone and performing dual luciferase assays
(data not shown). We next demonstrated that both the
pGM-GME and pXRL-GME plasmids were induced by
a factor of  100-fold upon stimulation (data not shown)
and showed that inclusion of the enhancer increased pGM
promoter activity by about 5 to 10 fold in CEM and
Jurkat cells (Figure 3). The introduction of single GG to
CC mutations within the position 443 or 452 motifs led to
a  3-fold reduction of activity in CEM cells and to a
 2-fold reduction of activity in Jurkat cells (Figure 3).
The double mutation of both the position 443 and 452
TGTGG motifs essentially abolished enhancer activity in
CEM cells, and reduced activity of the enhancer in Jurkat
cells to  2-fold the activity of the promoter
alone (Figure 3). Hence, we have conﬁrmed that both
Runx1 sites are required for eﬃcient inducible enhancer
function.
Computational modelling of a dimeric CBF complex
on a palindromic sequence
To determine (i) how overlapping Runx1 motifs might
accommodate two CBF complexes, and (ii) whether
dimer formation is potentially supported by interactions
between the two CBF complexes, we generated a
computer model of the dimer incorporating the Crystal
palindrome deﬁned in Figure 2. For this purpose, we
mapped the Runx1-CBFb coordinates determined by
Bravo et al for the single Runx1–CBFb–DNA complex
(11) onto the two Runx1 motifs within GM-CSF
enhancer sequence ATGTGTGGCTGCCCACAAAAC.
The core of the DNA binding regions, and in particular
the GG core elements, were aligned to those in the palin-
dromic sequence in order to preserve the geometry of the
interaction between Runx1 and DNA. Two major as-
sumptions were made when modelling the structure of
the dimeric CBF complex: ﬁrst, that each individual
CBF complex will recognize the DNA binding region
comparably to the monomeric form as reported by
Bravo et al., and second, that each individual CBF
complex would not undergo major conformation
changes when forming the dimeric CBF complex.
The raw structural model of the dimeric CBF complex
presented some minor steric clashes between the two CBF
complexes. In particular, some atoms of residues located
in the interface between the CBFb subunits and the bE0-F
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atomic distance inferior to the sum of van der Waals radii
(data not shown). The reasons for this are because (i)
during the modelling of the complex, the DNA molecule
containing the palindromic sequences was modelled as
straight B-DNA conﬁguration, and was kept rigid, and
(ii) the interactions between the Runx1 domains and
DNA was maintained in the same conformation as in
the crystal structure (11). However, when the complex
was subjected to an energy minimization step and a
short dynamic simulation, i.e. protein and DNA atoms
were allowed to relax and change conformation, these
steric clashes were largely resolved. PROCHECK did
not report any major stereochemical problems in the
minimized complex. Furthermore, the model of the
complex remained stable throughout the simulation and
the total energy of the complex converged to a minimum.
From the simulation, we were able to derive several
clusters of structures, and select representative examples
of each. From these, we selected the structure of
the complex that provided the best G-factor in
PROCHECK, and this is presented in Supplementary
Data File 1.
As represented in the model of this structure in
Figure 4A, two CBF complexes can comfortably bind sim-
ultaneously to the DNA binding sites without any major
steric impediment. The two GG core sequences of the
DNA motifs are separated by one half turn of helix and
exist in opposite orientations. This means that each Runx1
domain is rotated 180 degrees relative to the other with
respect to its interaction with the DNA binding site
(Figures 4A and B). The atomic analysis of this theoretical
complex reveals that atomic interactions between the C
terminal regions of the Runt domains and their DNA
binding sites are similar to the ones reported in the
crystal structure, including Arg80, Arg142, Thr 169, Asp
171, Arg174 and Arg177 [residue numbers as reported in
Bravo el al. paper (11); (Figure 4B)]. The model also
suggests that the dimer may be maintained by stabilizing
interactions between the two molecules of CBFb (Figure
4C). The proposed structural model predicts favourable
interactions between anti-parallel domains of CBFb that
allow optimal electrostatic pairing between polar residues
(Figure 4D).
DISCUSSION
It was previously assumed that Runx1 binding to DNA
principally involved the interaction of a single Runt
domain with one isolated TGYGG core sequence (5,6).
However, we have made the novel observation that two
molecules of Runx1 can assemble together on palindromic
sequences containing two closely spaced inverted repeats
of a TGYGG core sequence separated by 4bp. In this
arrangement, there is a 2bp overlap between the 8bp
TGYGGNNN DNA sequences contacted by the individ-
ual Runx1 complexes. Runx1 bound most eﬃciently as a
dimeric complex to DNA elements conforming to the con-
sensus TGTGGTTAACCACA or TGTGGTCGACCAC
A. In this conﬁguration, each of the repeated motifs
closely matches the TGTGGTTT or TGTGGTCA
consensus sequences that represent the most commonly
encountered Runx1 binding motifs. Binding of CBF
to the Ideal consensus palindromic Runx1 site TGTGG
TTAACCACA was more eﬃcient than to the
GM450 element, which lacks the preferred TGYGGT
motifs.
This work is to our knowledge the ﬁrst study that
reports the potential dimerization of CBF complexes on
DNA in a conformation similar to that observed for
dimers of the Rel homology domains of NFAT and
NF-kB family proteins. We are only aware of one other
report of Runx1 binding to a palindromic element (42).
However, in this instance, only one of the two TGCGG
Figure 3. Transient transfection assays of GM-CSF enhancer function.
Fireﬂy luciferase reporter gene plasmids were transfected into CEM
and Jurkat T cells. Cells were assayed after stimulation for 8h with
PMA and calcium ionophore. Plasmids contained either, just the
GM-CSF promoter (pGM) or the promoter plus the upstream
enhancer (pGM-GME), with or without speciﬁc mutations in either
or both of the TGTGG motifs located at positions 443 and 452.
Plasmids were cotransfected with the Renilla luciferase control
plasmid pXRL-GME. The data represent the averages of data
obtained from 3 to 6 independent transfections of each of 2 to 4 inde-
pendent plasmid preparations for each construct. The number of inde-
pendent transfections is indicated below each column (n). Error bars
indicate the standard error.
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actually contributed to Runx1 binding (underlined), and
there was no evidence for the assembly of dimeric CBF
complexes. It has also been reported that the t(8;21)
chromosomal translocation product Runx1-Eto is able
to bind to direct repeats of Runx1 consensus motifs as
found in the consensus sequence TGYGGTTN(0–13)TGC
GGT (42). In this situation, the mechanism of dimeriza-
tion is likely to be diﬀerent to that showed in our study
since in that report it was proposed that oligomerization
was mediated by Eto and not by Runx1.
As mentioned above, Runx1 is a distant relative of the
Rel and NFAT families of transcription factors, and it
shares with Rel domain factors the ability to recognize
GG core sequences. Runx1 is also a distant relative of
p53 which similarly binds as a dimer to palindromic se-
quences such as GGGCATGCCC (43) which have a con-
formation resembling both the NF-kB consensus and the
dimeric Runx1 site described here. While Runx1 resembles
NF-kB and NFAT with respect to its ability to bind sim-
ultaneously to both copies of an inverted repeat of the GG
motifs, there are signiﬁcant diﬀerences in the nature of the
Figure 4. Structural model of the dimeric form of CBF complex bound to the palindromic DNA sequence ATGTGTGGCTGCCCACAAAAC,
predicted from the crystal structure coordinates published by Bravo et al. for a single CBF:DNA complex. (A) Ribbon representation of the complex
from a lateral view using DNA as the reference point. Runx1 domains are depicted in magenta and green, and CBFb domains in yellow and cyan.
(B) Close-up view of the DNA binding site encircled in (A). Proteins and DNA are shown in ribbon and residues in direct contact with DNA labelled
in black boxes. The G bases within the core consensus TGYGG are labelled on the strand contacted by the indicated amino acids. (C) Ribbon
representation of the complex from a frontal view using CBFb as a the reference. (D) Surface potentials calculated for the interaction surfaces of the
CBFb domains. Positive charge is shown as blue, and negative charge is shown as red. Residues that potentially mediate the interactions between
the two CBFb domains are labelled in yellow. The predicted polar interactions between the antiparallel sequences are indicated by the dashed
lines between the linear representation of the sequences. In this view, the interacting surfaces depicted within bracketed regions in (C) have been
rotated 90 .
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NFAT (18,20,21) and NF-kB (10) each bind as dimers
to sequences resembling GGAAATTCC or GGAGACT
CC, Runx1 assembles as a dimer on sequences resembling
GGTTAACC. Runx1 also diﬀers substantially from
NF-kB with regard to the fact that NF-kB is not able
to use a single Rel domain to bind to a single GG motif.
In this respect, Runx1 has more in common with NFAT
than with NF-kB. Runx1 and NFAT both frequently
cooperate with other classes of transcription factor, but
still retain the ability to bind to DNA eﬃciently to a single
GG core element via a single Rel-like DNA-binding
domain.
Based on the in vitro binding of puriﬁed truncated
proteins, there was no evidence for cooperativity in the
binding of the recombinant CBF complexes that contain
just the Runt domain of Runx1. Nevertheless, it was
apparent from the in vivo footprinting that both of the
Runx1 sites within the GM450 element were eﬃciently
occupied simultaneously inside activated cells at about
half of all sites, raising the possibility of cooperativity in
the assembly of the dimeric complex. Furthermore,
assembly of dimeric Runx1 complexes appeared to be
more eﬃcient with full length naturally occurring
Runx1/CBFb complexes present in nuclear extracts than
with the truncated recombinant Runx1/CBFb. Additional
evidence for cooperativity was provided by competition
studies showing that a dimeric site was a substantially
stronger binding site than an equivalent single binding
site. This may be because Runx1 also contains a
homodimerization domain at the C terminus that is
absent in the recombinant Runx1 (17). It has been previ-
ously established that this interaction domain promotes
Runx1:Runx1 interactions between separated Runx1
sites. This same domain could also potentially help to sta-
bilize the dimeric complex and support cooperative
binding at palindromic Runx1 sites. The structure of the
C terminal region of Runx1 is unknown, partly because
much of it is unstructured, and partly due to technical
diﬃculties associated with preparing full-length recombin-
ant Runx1. However, from the proposed model structure
of the dimer it is evident that the C terminal portions of
the Runt domains cross over the DNA helices on opposite
sides of the DNA. Hence, this allows for the possibility
that the CBF dimer encircles the DNA by forming close
CBFb:CBFb interactions on one side, and Runx1 C
terminal interactions on the opposite side of the helix. If
the C-terminal region does contain unstructured domains,
it is likely to be ﬂexible enough to accomplish this. It is
also likely that within the nucleus, the dimeric CBF
complex exists as a higher order complex with multiple
other regulatory factors that would act to further stabilize
such a complex. Further genome-wide analyses will be
required to determine how often Runx1 sites within the
genome do in fact function as dimeric sites.
SUPPLEMENTARY DATA
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